According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...

The scholarship will pay for 4 years of tuition, fees and books at an Indiana public or private nonprofit college or ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

Shares of Eli Lilly & Co. LLY sank 0.24% to $772.00 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...

Boone County battled a number of challenges and achieved unprecedented successes in 2023. And the previously sleepy, agricultural county's economy, housing and culture will never be the same as before ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Shriram Properties: Realty firm Shriram Properties announced the strategic sale of a 3.9-acre land parcel in Chennai to a ...

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to ...